目的　探讨治疗肾综合征出血热（ＨＦＲＳ） 时，病毒唑（Ｒｉｂａｖｉｒｉｎ） 对肌酸磷酸激酶同工酶（ＣＫＭＢ） 的影响。方法　对１５５ 例肾ＨＦＲＳ患者在进行较大剂量Ｒｉｂａｖｉｒｉｎ 双盲随机对照治疗中对血清ＣＫＭＢ进行了动态观察，并将ＨＦＲＳ各期、各型病毒唑治疗组与对照组ＣＫＭＢ 水平进行了比较。结果　两组病例从发热期开始ＣＫＭＢ明显升高，恢复期时逐渐恢复正常，病毒唑组发热期ＣＫＭＢ 明显低于对照组，分别为５５－２５±１８－２５ＵＬ和６９－６３±２３－５２ＵＬ（ Ｐ＜ ０．０５） ；重、危型病毒唑组ＣＫＭＢ明显低于对照组，分别为４７－７４±２４－８２ＵＬ和６６－０８±２５－０１ＵＬ（ Ｐ＜０．０５） 。结论　较大剂量病毒唑的早期应用可使ＨＦＲＳ患者血清中ＣＫＭＢ浓度下降 Objective To investigate the effects of ribavirin on creatine phosphokinase isoenzyme (CKMB) in the treatment of hemorrhagic fever with renal syndrome (HFRS). Methods A total of 155 cases of renal HFRS patients were treated with larger doses of Ribavirin double-blind randomized controlled trials of serum CKMB were observed and the HFRS stages, various ribavirin treatment group and control group CK  MB level Compare Results The two groups of patients from the onset of fever CK  MB was significantly increased recovery time gradually returned to normal, ribavirin group fever CK  MB was significantly lower than the control group, respectively 55-25 ± 18-25UL and 69- 63 ± 23-52UL (P <0.05). The levels of CKMB in the severe and dangerous ribavirin groups were significantly lower than those in the control group (47-74 ± 24-82UL and 66-08 ± 25-01U L (P <0.05). Conclusion Early application of larger doses of ribavirin may reduce the concentration of CK-MB in serum of HFRS patients